At this year’s congress of the European Association of Dermato-Oncology (EADO), current recommendations for the management of cutaneous squamous cell carcinoma (cSCC) were outlined. The first-line therapy remains complete excision with histologic incision margin control. Adjuvant radiotherapy may be considered depending on the risk of recurrence. In advanced non-resectable cSCC, immune checkpoint inhibition is considered first-line therapy. Chemotherapeutic agents or EGFR inhibitors may be used if contraindications exist. Follow-up should be risk-adapted and include lymph node ultrasonography in high-risk patients.
This content is machine-translated. Please contact us if you need professional translation services.
- DERMATOLOGIE PRAXIS